248 related articles for article (PubMed ID: 34770742)
1. Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach.
Lahnif H; Grus T; Pektor S; Greifenstein L; Schreckenberger M; Rösch F
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770742
[TBL] [Abstract][Full Text] [Related]
2.
Sinnes JP; Bauder-Wüst U; Schäfer M; Moon ES; Kopka K; Rösch F
EJNMMI Radiopharm Chem; 2020 Nov; 5(1):28. PubMed ID: 33242189
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
Robu S; Schottelius M; Eiber M; Maurer T; Gschwend J; Schwaiger M; Wester HJ
J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.
Schottelius M; Wurzer A; Wissmiller K; Beck R; Koch M; Gorpas D; Notni J; Buckle T; van Oosterom MN; Steiger K; Ntziachristos V; Schwaiger M; van Leeuwen FWB; Wester HJ
J Nucl Med; 2019 Jan; 60(1):71-78. PubMed ID: 30237214
[TBL] [Abstract][Full Text] [Related]
6. Radiohybrid Ligands: A Novel Tracer Concept Exemplified by
Wurzer A; Di Carlo D; Schmidt A; Beck R; Eiber M; Schwaiger M; Wester HJ
J Nucl Med; 2020 May; 61(5):735-742. PubMed ID: 31862804
[TBL] [Abstract][Full Text] [Related]
7. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
[TBL] [Abstract][Full Text] [Related]
8. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, Labeling and Preclinical Evaluation of a Squaric Acid Containing PSMA Inhibitor Labeled with
Greifenstein L; Engelbogen N; Lahnif H; Sinnes JP; Bergmann R; Bachmann M; Rösch F
ChemMedChem; 2020 Apr; 15(8):695-704. PubMed ID: 32057189
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Evaluation of
Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo evaluation of the bifunctional chelator NODIA-Me in combination with a prostate-specific membrane antigen targeting vector.
Läppchen T; Kiefer Y; Holland JP; Bartholomä MD
Nucl Med Biol; 2018 May; 60():45-54. PubMed ID: 29571066
[TBL] [Abstract][Full Text] [Related]
12.
Young JD; Abbate V; Imberti C; Meszaros LK; Ma MT; Terry SYA; Hider RC; Mullen GE; Blower PJ
J Nucl Med; 2017 Aug; 58(8):1270-1277. PubMed ID: 28408532
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers.
Xu J; Cai F; Luo Z; Fan W; Dai J; Cui J; Li S; Geng C; Zheng Q; Wang Z; Tang X
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2618-2633. PubMed ID: 35347438
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, radiolabeling, and pre-clinical evaluation of [
Ghiani S; Hawala I; Szikra D; Trencsényi G; Baranyai Z; Nagy G; Vágner A; Stefania R; Pandey S; Maiocchi A
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2351-2362. PubMed ID: 33420915
[TBL] [Abstract][Full Text] [Related]
15. Optimization of Labeling PSMA
Eppard E; Homann T; de la Fuente A; Essler M; Rösch F
J Nucl Med; 2017 Mar; 58(3):432-437. PubMed ID: 28082433
[TBL] [Abstract][Full Text] [Related]
16. In Vitro and In Vivo Characterization of an
Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer.
Weineisen M; Simecek J; Schottelius M; Schwaiger M; Wester HJ
EJNMMI Res; 2014 Dec; 4(1):63. PubMed ID: 26116124
[TBL] [Abstract][Full Text] [Related]
18. Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals.
Wüstemann T; Bauder-Wüst U; Schäfer M; Eder M; Benesova M; Leotta K; Kratochwil C; Haberkorn U; Kopka K; Mier W
Theranostics; 2016; 6(8):1085-95. PubMed ID: 27279903
[TBL] [Abstract][Full Text] [Related]
19. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W
J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034
[TBL] [Abstract][Full Text] [Related]
20. Molar Activity of Ga-68 Labeled PSMA Inhibitor Conjugates Determines PET Imaging Results.
Wurzer A; Pollmann J; Schmidt A; Reich D; Wester HJ; Notni J
Mol Pharm; 2018 Sep; 15(9):4296-4302. PubMed ID: 30011372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]